LNTH Q3 2021 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$5B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$102M+15.3% YoY

Gross Profit

$43M41.8% margin

Operating Income

-$14M-14.0% margin

Net Income

-$13M-13.1% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+1.0%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$2M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$848M

Total Liabilities

$348M

Stockholders' Equity

$499M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$102M	$89M	+15.3%
Gross Profit	$43M	$36M	+17.7%
Operating Income	-$14M	-$5M	-172.9%
Net Income	-$13M	-$6M	-110.1%

Revenue Segments

Product

$97M33%

Total Precision Diagnostics

$88M30%

DEFINITY

$58M20%

Techne Lite

$23M8%

Radiopharmaceutical Oncology

$9M3%

Other Precision Diagnostics

$8M3%

License and Royalty Revenues

$5M2%

Strategic Partnerships And Other

$5M2%